Phase 1 study of CT-0508 in patients with HER2+ peritoneal cancer
Latest Information Update: 30 Mar 2023
At a glance
- Drugs CT 0508 (Primary)
- Indications Peritoneal cancer
- Focus Adverse reactions
Most Recent Events
- 07 Mar 2023 According to a Carisma Therapeutics media release, Carisma Therapeutics merged with the Sesen Bio. The combined companies are named as Carisma Therapeutics.
- 22 Sep 2022 New trial record
- 21 Sep 2022 According to a Sesen Bio media release, data is expected over the next 18 months.